A $7.9 Billion Fund Dumps These 3 Stocks

Michael Douglass • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 18, 2026

Alexander's Images, Erik G from Pexels via Canva

Key Takeaways

  • Montanova Capital, which manages $7.87 billion, had sold all of its Advanced Micro Devices, Arcus Biosciences and Ferguson Enterprises shares by Sept. 30, according to its latest 13F.
  • Since the quarter ended, AMD has fallen 13%, Arcus has fallen 47% and Ferguson has risen 5%.
  • Analysts’ average price targets are 31% above AMD’s price, 150% above Arcus’s and 17% above Ferguson’s.
  • AMD is the sale that looks weakest: its consensus target is worth only about 26x analysts’ 2028 earnings estimate, below its five-year average multiple.

Montanova Capital’s 13F for the quarter ended Sept. 30, filed Nov. 16, shows three positions gone: Advanced Micro Devices (AMD), Arcus Biosciences (RCUS) and Ferguson Enterprises (FERG). The firm manages $7.87 billion in all, and the 13F lists $3.63 billion of US stocks across 88 positions.

A 13F only shows what a fund held on the last day of a quarter, so it doesn’t say when Montanova sold or what it got. What we can see is how far Wall Street disagrees with the exit, and on one of these stocks it disagrees a lot.

TIKR tracks 54 analysts on AMD. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on AMD, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See AMD’s Analyst Ratings

AMD’s target doesn’t need a stretch

AMD was the biggest of the three. At June 30, Montanova held 257,240 shares worth $149 million, which was 3.1% of its 13F stocks. By Sept. 30 it held none. The stock has fallen 13% since the quarter ended and is 24% below its 52-week high.

The business news has been good. Anthropic, Meta, Microsoft, OpenAI and Oracle already run workloads on the first Helios racks, and production is scaling sharply in the fourth quarter. There’s a new problem, though. On Nov. 16, new US export rules began requiring licenses for advanced AI chips shipped to Indonesia, Malaysia, Singapore, Thailand and Brazil, and AMD’s Instinct GPUs are covered.

Analysts have kept raising their targets anyway. The consensus target has more than doubled over the past year, to $657.74 from $277.27:

Line chart from TIKR of Advanced Micro Devices' analysts' consensus (mean) price target, $ per share, last year.
Advanced Micro Devices (AMD): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That’s 31% above the last close, and 54 analysts cover the stock. By my math, $657.74 is about 26x analysts’ 2028 earnings estimate of $25.52 a share. That’s below AMD’s five-year average of about 35x forward earnings. So the target doesn’t need a higher multiple, just for the estimates to hold.

What it cost AMD to win these customers is the main risk. OpenAI and Meta hold warrants for up to 320 million shares between them, 19.6% of the shares outstanding, and fourth-quarter gross margin guidance of about 55% is at the bottom of AMD’s long-term range.

Arcus fell by half, and its targets went up

Arcus was nearly as large a position: 4.78 million shares worth $147 million at June 30, also 3.1% of the fund’s 13F stocks. Since Sept. 30 it has fallen 47%, leaving it 48% below its 52-week high. In October, Arcus presented new ARC-20 data on its kidney cancer drug casdatifan and raised $288 million in gross proceeds by selling stock. Its third-quarter release says that money, plus the $694 million of cash and investments it held at Sept. 30, funds the company into 2029.

Analysts haven’t followed the stock down. Over the year the consensus target rose to $40.92 from $33.22:

Line chart from TIKR of Arcus Biosciences' analysts' consensus (mean) price target, $ per share, last year.
Arcus Biosciences (RCUS): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That target, from 15 analysts, is 150% above the last close, and even the lowest target, $23, is 40% above it. Arcus had nearly $1 billion of cash after the October raise (before fees and before what it has spent since). Its market value is $2.36 billion.

The catch is that a biotech still losing money rises or falls on its trials. The company expects enrollment in PEAK-1, its Phase 3 study in second-line kidney cancer, to finish in the next two to three months. More mature ARC-20 data is due in 2027.

Ferguson was the smallest sale, and the only one up since

Ferguson was the smallest of the three: 246,758 shares worth $59 million at June 30, or 1.2% of the fund’s 13F stocks. It’s also the only one that has risen since the quarter ended, up 5%, and it’s 8% below its 52-week high. The consensus target has climbed steadily over the year, to $291.23 from $258.41:

Line chart from TIKR of Ferguson Enterprises' analysts' consensus (mean) price target, $ per share, last year.
Ferguson Enterprises (FERG): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That’s 17% above the last close, from 24 analysts. Analysts are unusually close together: the lowest target, $235, is about 6% below the price, and the highest is $325. At about 20x forward earnings, Ferguson looks fairly priced to me.

AMD is the sale I’d question

Of the three, AMD is the sale I’d question most. The Street’s target assumes a lower multiple than AMD usually trades at, and five of the biggest AI buyers already run its racks. Arcus could pay off more, but only if its trials do. Ferguson is the easiest of the three to let go.

Montanova’s next 13F is due by mid-February and will show whether it bought any of them back. AMD’s fourth-quarter report in early February is the bigger test: a gross margin below 55%, the bottom of its long-term range, would mean Helios is costing more than the targets assume.

So what is AMD stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what AMD could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value AMD for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required